Terminated PHASE3 INTERVENTIONAL 1-arm NCT02375685

Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X) (EYEGUARD-X)

A Safety Open-label Study of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis Disease, an eXtension Study. The EYEGUARD-X Study

Sponsor: Institut de Recherches Internationales Servier

Conditions Chronic Uveitis

Interventions Gevokizumab

Updated 8 times since 2017 Last updated: Jan 2, 2020 Started: Aug 31, 2014 Primary completion: Nov 30, 2015 Completion: Nov 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Institut de Recherches Internationales Servier

See all terminations from Institut de Recherches Internationales Servier

This PHASE3 trial investigates Chronic Uveitis and is currently terminated or withdrawn. Institut de Recherches Internationales Servier leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Feb 2020 — Jan 2021 [monthly]

Terminated PHASE3

▶ Show 3 earlier versions

Jun 2018 — Feb 2020 [monthly]

Terminated PHASE3
Jun 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Jun 2017 [monthly]

Terminated PHASE3

First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut de Recherches Internationales Servier

Data source: Servier

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Coimbra, Portugal , Istanbul, Turkey (Türkiye) , London, United Kingdom , Milan, Italy , Monastir, Tunisia , Nantes, France , Nedlands, Australia , Seoul, South Korea , Taoyuan District, Taiwan and 3 more locations